Table 2.
Systemic disease parameters and safety variables
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| Hemoglobin, g/dL (RV: 11.0–15.0) | |||||
| Baseline | 13.8 | 13.1 | 13.4 | 12.0 | 12.8 |
| Posttreatment | 13.2 | 12.5 | 13.9 | 13.2 | 13.6 |
| Platelets, ×109/L (RV: 12.5–34.3) | |||||
| Baseline | 18.5 | 11.5 | 11.2 | 19.0 | 12.2 |
| Posttreatment | 17.0 | 7.1 | 9.4 | 18.4 | 18.8 |
| Angiotensin‐converting enzyme (ACE), U/L (RV: 8.3–21.4) | |||||
| Baseline | 8.2 | 9.8 | 13.1 | 46.4 | 8.7 |
| Posttreatment | 7.8 | 7.0 | 8.8 | 19.2 | 8.5 |
| Uric acid, mg/dL (RV: 2.3–7.0) | |||||
| Baseline | 2.6 | 5.1 | 5.2 | 4.7 | 2.0 |
| Posttreatment | 0.7 | 2.2 | 2.4 | 3.9 | 3.7 |
| QTc interval (Fridericia), ms | |||||
| Baseline | 370 | 402 | 404 | 421 | 413 |
| Posttreatment (peak) | 401 | 387 | 394 | 402 | 435 |
RV, reference values. The effects of treatment were analyzed at the following times: patient 1, month 48; patients 2 and 3, month 36; patient 4, month 24; and patient 5, month 6.